Immunological monitoring of anticancer vaccines in clinical trials. - Wikidata - awgldk - TriplyDB

Immunological monitoring of anticancer vaccines in clinical trials.

Immunological monitoring of anticancer vaccines in clinical trials.

http://www.wikidata.org/entity/Q42734281

about

Lost in translation: animal models and clinical trials in cancer treatment Trial Watch: Proteasomal inhibitors for anticancer therapy Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment Therapeutic Vaccine Strategies against Human Papillomavirus.Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients Monitoring the immune competence of cancer patients to predict outcome.Counteracting antibiotic resistance: breaking barriers among antibacterial strategies.Therapeutic vaccines for cancer: an overview of clinical trials.Stem cell in alternative treatments for brain tumors: potential for gene delivery.The importance of the tumor microenvironment in the therapeutic management of cancer.Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist.

P2860

Q27000792-BBEDD2A1-523B-47EA-ADD3-0163935C11EE Q28082910-EAC5D754-7A1E-4724-8198-4B8A43757058 Q33587863-857A6851-CF7B-408B-96AA-4B5EEE2049AE Q33691858-D3BACEB6-B9D1-4950-9AFC-2DC2D6C08583 Q34410500-F0C3783A-4DBA-4757-B869-5493E4F7A612 Q35826752-8F3C91DE-4B96-4B11-95F3-FAA7599B4C05 Q36114649-53738D5D-6A7C-482B-B96F-9FDD532127E3 Q36248790-E1014C1F-F493-49FE-9719-0261165B04F0 Q36534662-260E1F1D-8905-4273-9E24-20F4AE10717B Q36777133-19DEEF60-6553-4E57-AE37-7CD4ED45ECB4 Q36977760-ACAB1A2A-6126-4D89-B823-87475D9D603E Q37530591-560C3533-711E-4716-8DE4-AD18081D8722 Q38184391-4AD0C709-4462-4883-B3B0-A3CBFC5218C3 Q38216443-5719B74E-940E-4380-9BE2-15FE618F2891 Q38227030-68025889-0E36-45FF-8791-614242FDD5B1 Q38521752-58E21A29-EA18-4CDA-9F42-1ED8B6604C08 Q38534294-33B734D5-2A9A-4AB2-8CBC-458C6181AC40 Q39038777-9D108FB5-FBB1-4650-91B8-686F7340950B

P2860

Immunological monitoring of anticancer vaccines in clinical trials.

http://www.wikidata.org/entity/Q42734281

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Immunological monitoring of anticancer vaccines in clinical trials.

@en

Immunological monitoring of anticancer vaccines in clinical trials.

@nl

type

label

Immunological monitoring of anticancer vaccines in clinical trials.

@en

Immunological monitoring of anticancer vaccines in clinical trials.

@nl

prefLabel

Immunological monitoring of anticancer vaccines in clinical trials.

@en

Immunological monitoring of anticancer vaccines in clinical trials.

@nl

P1433

Q42734281-3CA69229-1638-41AC-9901-499705164CAF

P1476

Q42734281-A296799A-7DD0-49E0-AB22-9DC5BF7F84E5

P2093

Q42734281-62BBCA69-6BA0-4846-9293-B09CAC96CC9C

Q42734281-F39B6B46-8686-49BA-84A1-5C2986BD1C72

P2860

Q42734281-06344C69-E01A-4F8A-B196-31E3B7B586F4

Q42734281-0C7A8D8C-EAD9-4A09-8E8A-76BF79CAB27F

Q42734281-1B84F553-426B-496E-8C28-2A1195BEFC1D

Q42734281-24AA54D6-5C8C-430D-A487-24F252193323

Q42734281-2D8295F6-6E99-4DC5-B621-63E4E1C01DBA

Q42734281-38FC1520-683D-430F-8487-B6E28CE3F953

Q42734281-3B2A8254-F8D6-4C46-98B0-ACC3A978070E

Q42734281-411D2C12-0F65-4F7B-913A-683D2BFAFEA8

Q42734281-4E85E4D4-8AD5-4A8A-B20F-C208B28C91B7

Q42734281-55497CFE-6E8E-46B4-81B3-96940ABF6842

P304

Q42734281-07358434-AD7B-42B4-B895-0D0F8FA7853B

P31

Q42734281-5507097B-7DC6-4D3F-B45C-04CE08DAC9E5

P356

Q42734281-C524D63A-D07C-46B0-8987-9AC345DEAF08

P433

Q42734281-B28309FC-39DA-4C20-AA8A-16000730E952

P478

Q42734281-4C690593-4FF7-46E4-B04D-51E57D6C402B

P577

Q42734281-552D9BD0-A82E-4DD8-8BA6-7BDE7194D9A1

P5875

Q42734281-6924E41B-EBE2-41EB-B0D6-55E49A3B05C1

P698

Q42734281-69101791-2E9D-43CE-A68A-C27DDA4A2F2D

P921

Q42734281-A0C69849-445D-435D-AB21-492D2B239C7D

P932

Q42734281-2431FF85-023F-402C-A024-B3668BC64975

P356

P1433

P1476

Immunological monitoring of anticancer vaccines in clinical trials.

@en

P2093

Atsushi Aruga

http://www.w3.org/2001/XMLSchema#string

Chizuru Ogi

http://www.w3.org/2001/XMLSchema#string

P2860

The immune contexture in human tumours: impact on clinical outcome

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

NGcGM3 ganglioside: a privileged target for cancer vaccines

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

P304

e26012

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.26012

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257251375

http://www.w3.org/2001/XMLSchema#string

P698

24083085

http://www.w3.org/2001/XMLSchema#string

P921

P932

3782518

http://www.w3.org/2001/XMLSchema#string